Biogen, Eisai, Aardvark Therapeutics, etc.

Stay informed on the latest in biotech by signing up for the newsletter. Recent developments include scientists discovering a way to target aggressive pediatric tumor cells using tumor-suppressor genes. A U.K. health agency’s decision on an ALS drug by Biogen raises concerns about access to genetic medicines. Generic versions of diabetes drugs could be more affordable and still profitable. Aardvark Therapeutics is preparing for a $200 million IPO after promising early-stage trials with ARD-101 for Prader-Willi syndrome. The company’s drug suppresses hunger cravings and could be approved in 2026. Stay updated on industry news and developments in biotech.

Source link

error: Content is protected !!